Tilray (TLRY) Q1 2027 Earnings Call Transcript

Tilray reported record fiscal Q1 2027 revenue of $257.1 million, up 23% year over year, and gross profit of $77.5 million, up 35%; consolidated gross margin expanded 300 basis points to 30%. Adjusted EBITDA declined to $9.2 million from $10.2 million amid $8.8 million of international cannabis price compression and $1.7 million in additional fuel surcharges; the company reaffirmed fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million. BrewDog contributed $55.9 million in beverage revenue and reached profitability, while Tilray ended the quarter with $221.4 million in cash and marketable securities and reported a $40 million net loss.

Analysis

The key issue is earnings conversion, not portfolio breadth. Acquired BrewDog is doing much of the work behind beverage growth, while management acknowledged the legacy U.S. beverage business would have declined without it. Consolidated gross-margin expansion therefore does not yet establish durable organic growth or stronger cash generation. BrewDog’s reported profitability is encouraging but company-asserted and not quantified; verify segment EBITDA, operating cash flow and working-capital needs before capitalizing it.

The Carlsberg agreement could improve brewery utilization and strengthen distributor access, but revenue contribution is not equivalent to profit: production economics, profit-sharing terms, incremental selling costs and distributor execution are undisclosed. It may also intensify the portfolio/SKU and distributor-consolidation trade-offs for Tilray’s smaller U.S. beer brands. For Carlsberg, the arrangement offers U.S. reach without building a standalone route to market, but the financial contribution is not yet measurable.

International medical cannabis has a potentially favorable cost-and-volume setup, yet reported price compression shows that added capacity and shipment growth may not translate proportionally into earnings. Near term, fuel and pricing pressure challenge the reaffirmed EBITDA outlook; over 1–3 months, the test is whether seasonal second-half weighting appears in cash generation, not just guidance. Over 6–18 months, Carlsberg execution and Canadian excise/access policy are meaningful optionality, not underwritten earnings today. The $52 million of remaining principal due in June 2027 is manageable against stated liquidity but raises the importance of avoiding further cash burn or dilution. Contrarian view: diversification may reduce regulatory dependence, but can also obscure weak organic trends and execution complexity.

Key Decisions for Investors

• Avoid chasing TLRY on headline revenue growth; treat the setup as conditional rather than a confirmed earnings inflection. Reassess after the next report for positive operating cash flow, improving adjusted EBITDA, and quantified BrewDog contribution.
• Catalyst watch: track Carlsberg launch readiness and discloseable economics—profit share, utilization, incremental costs, and distributor commitments. Do not value the partnership as a material earnings stream until those are clearer.
• If seeking exposure, consider a small, defined-risk TLRY call spread only after evidence of sequential cash generation and stable-to-improving cannabis pricing; otherwise remain on the sidelines rather than paying for regulatory or beverage optionality.
• Falsify the constructive case if guidance is cut, second-half EBITDA fails to ramp, cash conversion weakens alongside debt obligations, or price compression persists despite higher medical volumes. A credible improvement in those metrics would strengthen the long case.